Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover
- 31 August 2008
- journal article
- Published by Elsevier BV in Molecular Immunology
- Vol. 45 (14), 3797-3803
- https://doi.org/10.1016/j.molimm.2008.05.020
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drugExpert Opinion on Drug Delivery, 2008
- Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopyProceedings of the National Academy of Sciences of the United States of America, 2008
- Complement evasion by human pathogensNature Reviews Microbiology, 2008
- In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in miceNature Nanotechnology, 2006
- Mammalian pharmacokinetics of carbon nanotubes using intrinsic near-infrared fluorescenceProceedings of the National Academy of Sciences of the United States of America, 2006
- Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin productionThe FASEB Journal, 2006
- Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicityToxicology, 2005
- PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performanceFEBS Letters, 2002
- Complement activation in vitro by the red cell substitute, liposome- encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1Transfusion, 1997
- Complement Activation in Rats by Liposomes and Liposome-Encapsulated Hemoglobin: Evidence for Anti-lipid Antibodies and Alternative Pathway ActivationBiochemical and Biophysical Research Communications, 1994